BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 19819536)

  • 21. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
    J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy.
    Perlmutter MA; Lepor H
    Urology; 2008 Mar; 71(3):501-5. PubMed ID: 18342197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW
    J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
    Haese A; Huland E; Graefen M; Hammerer P; Noldus J; Huland H
    J Urol; 1999 Apr; 161(4):1206-11. PubMed ID: 10081870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.
    D'Amico AV; McLeod DG; Carroll PR; Cullen J; Chen MH
    Cancer; 2007 Apr; 109(7):1290-5. PubMed ID: 17315162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.
    Ellis WJ; Vessella RL; Noteboom JL; Lange PH; Wolfert RL; Rittenhouse HG
    Urology; 1997 Oct; 50(4):573-9. PubMed ID: 9338734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2010 Jun; 105(11):1541-7. PubMed ID: 19912191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy.
    Tollefson MK; Blute ML; Rangel LJ; Karnes RJ; Frank I
    J Urol; 2010 Sep; 184(3):925-9. PubMed ID: 20643452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
    Pruthi RS; Johnstone I; Tu IP; Stamey TA
    Urology; 1997 May; 49(5):737-42. PubMed ID: 9145980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
    Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
    J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
    Witherspoon LR; Lapeyrolerie T
    J Urol; 1997 Apr; 157(4):1322-8. PubMed ID: 9120931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
    Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
    Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of biochemical recurrence after radical prostatectomy.
    Molitierno J; Evans A; Mohler JL; Wallen E; Moore D; Pruthi RS
    Urol Int; 2006; 77(2):130-4. PubMed ID: 16888417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
    BaƱez LL; Sun L; Trock BJ; Han M; Partin AW; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ
    J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
    Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.